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Abstract
Inositol and phosphoinositide signaling pathways represent major regulatory systems in
eukaryotes. The physiological importance of these pathways is amply demonstrated by the variety
of diseases that involve derangements in individual steps in inositide and phosphoinositide
production and degradation. These diseases include numerous cancers, lipodystrophies and
neurological syndromes. Phosphatidylinositol transfer proteins (PITPs) are emerging as
fascinating regulators of phosphoinositide metabolism. Recent advances identify PITPs (and
PITP-like proteins) to be coincidence detectors, which spatially and temporally coordinate the
activities of diverse aspects of the cellular lipid metabolome with phosphoinositide signaling.
These insights are providing new ideas regarding mechanisms of inherited mammalian diseases
associated with derangements in the activities of PITPs and PITP-like proteins.
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Inherited mammalian diseases ultimately reduce themselves to derangements in activities of
proteins. For enzymes, deficiencies in activity are understood in terms of the substrates and
products of defined chemical reactions. For scaffolding or structural proteins, compositions
of protein complexes describe the defects. However, in other cases, the proteins (or protein
domains) of interest resist simple functional definitions. Such molecules are often
understudied for these reasons, and phosphatidylinositol transfer proteins (PITPs) fall into
this category. The goal of this review is to summarize the important physiological functions
executed by these proteins with an emphasis on the inherited diseases associated with altered
activities of individual PITPs or PITP-like proteins. With regard to more mechanistic
questions, we discuss recent advances that provide new insights into how these proteins
operate at the molecular level. Of particular emphasis are emerging concepts regarding how
PITPs integrate phosphoinositide signaling with diverse aspects of intracellular lipid
metabolism. These insights provoke fresh perspectives from which to view potential
mechanisms of mammalian PITP diseases.
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The involvement of phosphorylated forms of D-myo-inositol (Ins-phosphates) and
phosphatidylinositol (phosphoinositides) in eukaryotic signal transduction is well
documented [1]. Indeed, the breadth of inositide and phosphatidylinositol (PtdIns)-based
signaling has inspired some to anoint Ins as evolution’s favorite molecule [2]. This is not an
idle proclamation given the diversity of phosphorylated products that can be generated from
Ins-containing compounds. For example, yeast generate five phosphoinositides (PtdIns-3-P,
PtdIns-4-P, PtdIns-5-P, PtdIns-4,5-P2 and PtdIns-3,5-P2), while higher eukaryotes produce
seven (the five listed for yeast plus PtdIns-3,4-P2 and PtdIns-3,4,5P3). The case for Ins-
phosphates is more impressive. As each position of the six-member Ins ring can be
phosphorylated (and in at least several cases pyrophosphorylated), the cabal of possible
soluble Ins-phosphate species is immense (63 + Ins for monophosphates and 728 + Ins if
one imposes a limit of only two phosphates per Ins-OH). These statistics identify the
versatility of Ins as a six-bit chip where specific signaling information is encoded by a
unique combination of positionally specific phosphorylations on the Ins ring. The Ins-
phosphate chemical code is subsequently interpreted by proteins, which have the appropriate
Ins-phosphate binding specificities.
Use of Ins as a signaling scaffold, either in the form of a soluble Ins-phosphate or a
membrane-incorporated phosphoinositide, requires a fine coordination between biosynthetic
activities (PtdIns-kinases) and degradative processes (catalyzed by phospholipases and
phosphoinositide phosphatases). Comprehensive reviews focusing on the metabolism of Ins-
phosphates and phosphoinositides treat these issues in detail, and the reader is referred to
them [3–5]. In this regard, the physiological importance of Ins and PtdIns metabolism is
obvious. Defects in the enzymes that directly catalyze specific biosynthetic or degradative
reactions in Ins-phosphate or phosphoinositide metabolic pathways result in a variety of
inherited human diseases [6,7]. The landscape assumes even greater complexity when issues
of spatial or temporal control of phosphoinositide production and degradation (i.e., issues
critical to biological regulation of Ins-phosphate and phosphoinositide signaling) are
considered. In this article, we limit the discussion to the production arm of phosphoinositide
signaling.
Present discussions of the roles for phosphoinositides in cell regulation focus on, first, the
function of these lipids as metabolic reservoirs for second messengers (e.g., diacylglycerol
and soluble Ins-phosphates), and second, their involvement in the formation of membrane-
binding platforms for specific proteins [8–10]. Regarding the latter context, the ability of a
mammalian cell to produce seven chemically distinct phosphoinositides allows for creation
of a diverse set of binding platforms. The chemical heterogeneity of phosphoinositides is in
turn interpreted by protein-binding motifs such as pleckstrin homology (PH) domains, Fab1,
YOTB, VAC1 and EEA1 (FYVE) domains, PX domains, and even basic patches on protein
surfaces that execute phosphoinositide binding by purely electrostatic mechanisms [8–10].
Discussions of phosphoinositide signaling are dominated by product-centric models that fail
to capture important dynamics that accompany production of these lipids. These discussions
also do not adequately describe the consequences these mechanisms have with regard to
functional diversification of phosphoinositide signaling. The principle message to be
delivered in this article is that we do not yet understand important aspects of how lipid
signaling is regulated in eukaryotic cells, nor do we understand how the larger lipid
metabolome is integrated with phosphoinositide signaling. An emerging concept that bears
on this theme that is a specific phosphoinositide generated by a specific lipid kinase can
nonetheless have multiple biological outcomes in a single-cell eukaryote [11–13]. Thus,
biological outcome is not solely determined by the chemical nature of the phosphoinositide,
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nor is it determined by the PtdIns kinase that produced it. Rather, biological outcome tracks
with nonenzymatic proteins that stimulate PtdIns kinase activities. These regulatory proteins
are the PtdIns/phosphatidylcholine (PtdCho)-transfer proteins (PITPs) and the data suggest
that these PITPs ‘instruct’ physiological outcomes for PtdIns kinase activities [11–13].
PITP-like protein domains hold similar potential for providing such instructive functions,
and these domains are found in intriguing contexts. The importance of PITPs and PITP-
domain proteins in eukaryotic cell biology and physiology is amply demonstrated by the
mammalian diseases associated with derangements in the function of such proteins. Herein,
we review the PITPs and mammalian diseases of PITP-like protein dysfunction.
Operational definitions for the PITPs
Sec14-like & START-like PITPs
All eukaryotes express PITPs. The so-called ‘classical’ PITPs (a purely historical definition)
mobilize PtdIns and PtdCho transfer between membranes in vitro. These PITPs bind PtdIns
and PtdCho in a mutually exclusive manner. PtdIns is the preferred binding substrate, and
the rate of PtdIns-transfer is some 20-fold greater than that for PtdCho [14]. This preference
reflects the greater affinity of PITP for PtdIns relative to PtdCho. At present, PITPs are most
often interpreted to function as lipid carriers that supply PtdIns, synthesized in endoplasmic
reticulum membranes, to membranes that are low in PtdIns (e.g., the plasma membrane) yet
execute an active phosphoinositide cycle [15]. The ‘nonclassical’ PITPs are designated as
such because these retain the ability to bind or transfer PtdIns, but do not conserve PtdCho-
binding or transfer activity [11,16,17]. The nonclassical PITPs, which, ironically, almost
certainly outnumber the classical versions, provide interesting cases for how the diversity in
lipid binding by PITPs and PITP-like proteins translates to the great diversity in biological
outcome for phosphoinositide signaling (see later).
Phosphatidylinositol transfer proteins are highly conserved. The conservation of PITPs
breaks down into two distinct branches based on their structural folds, which are the Sec14-
like PITPs and the START-like (StAR-related lipid transfer domain) PITPs. To date, all
START-like PITPs studied are classical PITPs, while Sec14-like proteins include both
classical and nonclassical varieties. As described in detail below, the Sec14 and START
folds are unrelated, although these do share some general properties. Whether Sec14-like
and START-like PITPs evolutionarily converge on common functional mechanisms, or
whether their shared transfer activities are purely coincidental, remains to be determined.
Fungi, plants, metazoans and apicomplexan parasites are rich in Sec14-like proteins, and
these constitute an ancient and uniquely eukaryotic protein superfamily. The founding
member of this PITP class is yeast Sec14 [17–19]. As detailed later, the Sec14 superfamily
counts the mammalian retinaldehyde binding proteins, domains of Rho-GEF proteins, the
neurofibromin Ras-GAPs and plant phosphoinositide binding proteins among more than
1500 of its members. Even simple eukaryotes such as yeast express multiple Sec14-like
proteins (Saccharomyces cerevisiae expresses six), while Drosophila melanogaster,
Caenorhabditis elegans, mice, humans and plants (e.g., Arabidopsis thaliana) each express
more than 20 Sec14-domain proteins. By contrast, the START-like PITP family is a rather
sparse one [17,20] and is further subdivided into type 1 and 2 PITPs. The soluble START-
like PITPs (type 1 PITPs) have an approximate molecular weight of 35 kDa and are
homologous to each other. The type 2 proteins are larger constructions with a domain
homologous to the entire type 1 START-like PITP sequence appended to the N-termini of
large membrane-associated modules. The START-like PITP family is not expanded to a
large degree from flies (two type 1 PITPs and one type 2 PITP) to humans (three type 1
PITPs and two type 2 PITPs). The type 2 PITPs exhibit complex modular arrangements, but
the PITP domain is the essential component of at least one of these proteins – the
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approximately 900-amino acid Drosophila type 2 PITP RdgB. This protein is required for
the fly photoresponse – a high-capacity phosphoinositide signaling system. However, the
280-residue PITP domain of RdgB (comprises only ~25% of the total RdgB protein
sequence) is both necessary and sufficient for rescue of the retinal degeneration associated
with RdgB inactivation, and for restoration of a seemingly wild-type photoresponse in flies
lacking the full-length protein [21]. This review focuses on type 1 PITPs because these are
better represented in models for mammalian disease.
The slippery faces of lipid transfer activities
As PITPs are not enzymes, translation of PITP-associated lipid exchange activities to
biochemical or biological mechanisms is difficult. While discussions of biological
mechanisms for PITP function remain anchored to the historical concept that PITPs are bona
fide carrier proteins that deliver lipid from one intracellular membrane system to another
(Figure 1A), such arguments are inherently circular. That is, PITPs are defined on the basis
of an operational transfer assay of uncertain functional significance, and the transfer activity
is subsequently featured as the central cellular activity executed by the PITP. Arguments
that directly translate PITP in vitro transfer activities to facilitated mobilization of lipid
between intracellular membranes in vivo are wrapped in important biological assumptions.
One central assumption made in such transfer models is that lipid synthesis is restricted to a
few intracellular compartments. As our understanding of cellular lipid biosynthetic
capabilities grows, this assumption is coming under increasing fire.
Despite the general acceptance of lipid transfer mechanisms, there is little direct evidence to
support simple transfer models for any individual PITP. This evidentiary gap reflects the
difficulties in experimentally testing transfer models in physiologically relevant settings. Are
there other perspectives from which to view the PITP or lipid transfer problem? Insights
culled from studies on PITPs, particularly PITPs of the Sec14 superfamily, do indeed
suggest new and detailed mechanistic possibilities. The available evidence is most consistent
with Sec14, and other Sec14-like proteins, functioning as ‘primed’ lipid biosensors that
couple binding of lipids other than PtdIns (sensor function) to a PtdIns-presentation activity
(Figure 1B). The PtdIns-presentation function potentiates the PtdIns-kinase activity by
making PtdIns a better substrate for the enzyme. Thus, Sec14-like PITPs are engaged in the
action of small machines, or nanoreactors, where metabolic and signaling reactions are
integrated and the products are generated in a spatially and temporally appropriate manner.
We define a minimal nanoreactor as a functional interaction between a phospholipid-bound
PITP and a PtdIns kinase. ‘Nanoreactor’ models do not describe PITPs as transorganelle
lipid carriers, and offer new perspectives on how to interpret functions of PITP-like modules
in multidomain proteins. The Sec14 paradigm provides new ideas from which to view
mechanisms of PITP function and recent evidence suggests that these new concepts might
extend to type 1 PITPs.
Sec14-like PITPs as molecules
Sec14 & integration of PtdIns/phosphatidylcholine metabolic signals
Sec14, the major yeast PITP, is required for membrane trafficking through the trans-Golgi
network (TGN) or endosomal system. It acts in a retrograde ‘endosome to TGN’ trafficking
capacity, and is essential for yeast cell viability [13,17,22]. ‘Bypass Sec14’ mutations, that
permit yeast viability in the absence of the normally essential Sec14, provide unique
avenues for diagnosing how Sec14 translates its PtdIns/PtdCho-transfer activities to
biological function [23–28]. The ‘bypass Sec14’ mutants reveal a remarkably intimate
coupling between the cellular requirement for Sec14 function and activity of the CDP–
choline pathway for PtdCho biosynthesis. That is, inactivation of the CDP–choline pathway
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obviates the cellular Sec14 requirement [24,25]. These studies also show that yeast mutants
deranged for phospholipid biosynthesis, such that PtdIns is the major membrane
phospholipid (~40 mol% compared with 20 mol% for wild-type yeast and 5 mol% for
mammalian cells; mol% represents a unit describing the fractional contribution of a specific
phospholipid species to the total number of phospholipid molecules in, in this case, the cell),
still require Sec14 for cell viability. A PtdIns surfeit of this magnitude should present a
condition where PITP-driven PtdIns-supply requirements are no longer necessary; however,
the Sec14 requirement for cell viability and TGN/endosomal function stands. These various
data are difficult to reconcile with PtdIns- and PtdCho-transfer models for Sec14 [24,25].
Rather, ‘bypass Sec14’ mutants identify Sec14 as an essential integrator required for proper
coordination of a specific arm of PtdCho-metabolism with phosphoinositide synthesis. This
integration is essential for membrane trafficking through the TGN/endosomal system
[12,13,17,24–28].
Anatomy of phospholipid exchange by Sec14-like PITPs
All ideas regarding mechanisms of PITP function assign an important role for the
phospholipid-exchange activities of these proteins. These remarkable activities are sustained
by thermal energy alone and require no additional cofactors. What are the mechanics of the
phospholipid exchange reaction from the perspective of the PITP and from the perspective
of phospholipid ligand? Crystallographic studies demonstrate the Sec14-domain
(smart00516) to constitute an approximately 280-amino acid, two-lobed, globular structure
that encases a large hydrophobic cavity, which defines the phospholipid-binding pocket
[12,29,30]. Electron paramagnetic resonance measurements report that the hydrophobicity
parameters of the pocket are such that this cavity, from the perspective of the phospholipid
ligand, offers an environment that is similar to that provided by a membrane leaflet. Thus,
incorporation of a phospholipid from a membrane into the Sec14 interior, and vice versa, is
primarily driven by partitioning of a phospholipid between two chemically equivalent
environments [31]. How the phospholipid is brought to the point where such a partitioning
choice is available remains unclear.
Access to the binding pocket is gated by a helical substructure whose configuration is
flipped open in apo-Sec14 conformers that occur when Sec14 is docked onto membrane
surfaces (Figure 2A) [12,29,32]. The helical gate is closed in holo-Sec14 conformers (Figure
2B), and these represent solution configurations for Sec14::PtdIns and Sec14::PtdCho
complexes. The transitions between the open and closed conformers that accompany
phospholipid binding and release on membrane surfaces are dominated by an 18Å
displacement of the helical gate (Figure 2). Helical gate dynamics are controlled by a
compact ‘gating module’ that regulates an extensive H-bond network through which
conformational information is transduced to the helical gate upon membrane binding [32].
The core engineering of a Sec14 nanoreactor
How does Sec14 use its PtdIns- and PtdCho-transfer activities to integrate PtdCho
metabolism with phosphoinositide synthesis? The solution to this problem is encoded in the
way Sec14 binds to its phospholipid ligands. The most remarkable feature of Sec14 (and
Sfh1) is the striking difference in the binding poses of PtdIns and PtdCho upon
incorporation into the hydrophobic pocket (Figure 3). While the acyl chain regions of each
phospholipid occupy overlapping physical space, the respective headgroups are stabilized by
distant regions of the hydrophobic pocket. This curious and unexpected engineering for how
Sec14 binds distinct phospholipid headgroups is of functional significance as heterotypic
phospholipid exchange capability must be housed within individual protein molecules in
order for Sec14 to potentiate PtdIns 4-OH kinase activities in vivo [12,13]. In principle,
Sec14 employs a coincidence-detection strategy that integrates PtdCho metabolic
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information with the action of PtdIns 4-OH kinases – in other words, Sec14 employs its
heterotypic PtdIns- or PtdCho-exchange activities to sense (bind) local PtdCho and so prime
a ‘PtdIns-presentation’ unit, or nanoreactor, that stimulates PtdIns 4-OH kinases. The
necessity for such a complex program stems from the biological inadequacy of PtdIns 4-OH
kinases as interfacial enzymes when confronted with PtdIns substrates incorporated into
genuine membrane bilayers [12,13].
Primed PtdIns-presentation models versus lipid transfer models
The concept that Sec14 employs heterotypic exchange in a concerted phospholipid sensing/
presentation cycle portrays the associated in vitro PtdIns- or PtdCho-transfer activities in a
very different light than do lipid transfer models. An attractive aspect of presentation/
nanoreactor models are these frame-specific and experimentally testable hypotheses. Several
are presented here for discussion. While the questions are framed in the context of Sec14,
each of these ideas generates questions that generally pertain to functional interpretations of
PITPs and other lipid transfer proteins.
Presentation models do not demand physical transfer of lipids from one intracellular
destination to the other – it is the cycle that is the key. How many average exchange cycles
does Sec14 complete during its membrane dwell time? Presentation models embrace the
possibility that many such cycles are executed by Sec14 during each short episode where the
protein associates with a membrane, while transfer models describe a scenario where there is
one exchange cycle per membrane association event.
Is physical disengagement of Sec14 from membranes required for execution of biological
function? The simplest transfer models demand this be the case, although membrane
‘contact site’ models leave open the possibility that a membrane-bound Sec14 could still
retain biological function. Space limitations prohibit detailed discussions of ‘contact-site’
models but the concept is reviewed elsewhere [33,34], and readers are referred to these for
further information. Presentation models easily accommodate scenarios where Sec14 (or
other LTP domains) are biologically functional as membrane-bound multidomain molecules.
Is a complete cycle of exchange obligatory for function, or are abortive exchanges
productive? Transfer models demand completion of a pick-up and delivery cycle – not so for
presentation models. The ‘presentation’ concept describes a trapping of PtdIns molecules in
a transitory state – one where the PtdIns is neither fully membrane- nor protein-incorporated
– and is therefore particularly vulnerable to modification by PtdIns 4-OH kinases. Such a
mechanism posits that an invading PtdIns molecule is prevented from fully incorporating
into the Sec14 hydrophobic pocket by a leaving PtdCho. Such a frustrated PtdIns molecule
can be marked by a PtdIns 4-OH kinase without the PtdIns ever having fully incorporated
itself into the Sec14 hydrophobic pocket. Interestingly, PtdCho enters and exits the
hydrophobic pocket much more slowly than PtdIns. This raises the possibility that multiple
rounds of abortive PtdIns incorporation may occur per single PtdCho egress event, thereby
providing a physical picture of priming. A formal corollary to this hypothesis is that an
appropriate covalent adduct of PtdCho, or any other suitable steric obstacle, within the
Sec14 hydrophobic pocket might still be compatible with the capability of Sec14 to
stimulate PtdIns 4-OH kinase activity, even though this arrangement is physically
incompatible with lipid exchange.
What trajectories do lipid molecules follow during entry or exit from the Sec14 hydrophobic
pocket? Do PtdIns and PtdCho share similar trajectories (e.g., same entry and exit portals),
or do these trace different paths? Reductionist questions of this sort are not particularly
important for understanding interorganelle lipid transfer mechanisms. However, solutions to
these questions are central to an understanding of how presentation/nanoreactor mechanisms
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work because heterotypic phospholipid trajectories define the operative anatomy of the
presentation process.
Finally, how are Sec14 ‘sensing’ territories defined? This question relates to how spatial
regulation of phosphoinositide synthesis is controlled. We define a sensing territory as that
area on a given membrane where the PITP is executing biologically productive heterotypic
phospholipid exchange reactions (i.e., result in enhanced phosphoinositide synthesis). For
membrane-tethered versions of Sec14-like PITPs (see later), the spatial restriction of the
tethering (by accessory membrane-binding domains, membrane binding via protein–protein
or protein–lipid interactions intrinsic to the Sec14 domain), determines the sensing territory.
However, the cytosolic Sec14 potentiates the activities of distinct PtdIns 4-OH kinases that
reside in distinct intracellular compartments within the same cell. How is this accomplished
for such a nomadic PITP? Transient interactions of Sec14 with a guiding platform (protein
or lipid) might contribute at some level. The PtdIns 4-OH kinase itself is an obvious
candidate for such a landmark. However, the ability of the structurally unrelated vertebrate
type 1 PITPs to act as functional Sec14 surrogates in yeast argues against privileged Sec14–
PtdIns 4-OH kinase interactions [35–37]. As discussed in detail elsewhere [13], more
stochastic arrangements can still be biologically productive (i.e., result in enhanced
synthesis of phosphoinositide).
A PITP-centric strategy for linking lipid metabolism to phosphoinositide signaling
The Sec14 fold is an evolutionarily ancient and versatile one, conserved from single-cell
eukaryotes to humans. Its expansion throughout the eukaryotic kingdom reflects an
impressive diversification of the unit to bind a wide variety of lipids and lipophilic
molecules. Primary sequence comparisons identify well-conserved crystal structure-based
PtdIns-binding signatures in many of these proteins; however, PtdCho-binding signatures
are not extensively conserved [12,13]. These binding signatures, or bar codes, represent the
translation of 3D structural information into a 2D primary sequence read-out. The PtdIns-
binding bar code is depicted in Figure 4. It is an attractive proposition that Sec14
superfamily proteins couple metabolism of a diverse set of lipids or lipophilic molecules
(i.e., of Sec14-protein ligands) with phosphoinositide synthesis, thereby coordinating
disparate arms of the lipid metabolome with common phosphoinositide signaling pathways.
These models might generally apply to PITPs and PITP-domain proteins. We highlight these
new perspectives in this article.
Mammalian Sec14-domain protein disorders
Mammals employ the versatile Sec14 fold in diverse ways – in some cases as standalone
domains or, more frequently, as modules that contribute to more complex arrangements in
multidomain proteins. Owing to the sheer scope of the Sec14 superfamily, only a limited
sampling of proteins can be summarized here. We restrict attention to those Sec14-like
proteins whose dysfunction is related to inherited mammalian disease.
Standalone Sec14-like proteins & disease
The standalone Sec14-like proteins regulate a variety of cellular events, including the visual
cycle, vitamin E homeostasis, apoptosis and membrane trafficking. Individual derangements
in these standalone Sec14-like proteins primarily manifest themselves as neurological
disorders. Some outstanding examples are summarized later. In some cases, the identities of
the ligands that occupy the hydrophobic pocket are known. For others, no ligand that
incorporates into the protein interior is known. However, many Sec14-like proteins exhibit a
recognizable PtdIns-binding barcode [12]. Whether these proteins do indeed bind to PtdIns,
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and whether these are capable of channeling PtdIns to phosphoinositide synthesis, raises
interesting questions for study.
α-tocopherol transfer protein & vitamin E status—Ataxia with vitamin E deficiency
(AVED) is an autosomal recessive, progressive neurodegenerative disorder caused by
deficiencies in the Sec14-like α-tocopherol binding protein (αTTP) [38]. This human disease
is hallmarked by low vitamin E levels, and manifests itself through hyporeflexia, ataxia,
muscle weakness, dementia, visual field contraction and even complete blindness, and
cardiac arrhythmias [39]. Treatment for AVED involves high doses of orally administered
vitamin E (1200–1500 mg/day), which restores vitamin E to normal circulating levels of
0.5–2.0 mg/dl. Indeed, if administered prior to extensive progression of disease, either pre-
or postsymptomatic delivery of vitamin E can effectively reverse, or entirely prevent, AVED
[40]. Mice engineered for αTTP deficiency similarly exhibit low levels of circulating
vitamin E, and present late-onset neurological deficits [41–43].
At least 25 mutations have been described in the 278-amino acid, αTTP structural gene
(TTPA). These fall into two clinical categories: those resulting in severe AVED with early
onset, and those characterized by milder AVED with late onset [44]. Several mutations in
conserved residues (e.g., R59W, E141K and R221W) compromises α-tocopherol (α-TOH)
binding or transferring and result in severe AVED [45]. By contrast, the R192H, H101Q and
A120T missense substitutions involve partially conserved residues, do not strongly
compromise α-TOH binding/transfer and result in mild AVED [46,47].
It is generally accepted that αTTP is the master regulator of plasma vitamin E levels. In
comparative studies, αTTP preferentially binds and transfers α-TOH between membranes in
vitro relative to other tocopherols [48–50]. It is thought that αTTP employs such a transfer
activity to channel α-TOH to a secretory, rather than a degradatory, fate [51,52]. Some
models suggest that αTTP does so by mediating direct transport of α-TOH from endosomes
to the plasma membrane for incorporation into VLDLs in an ABCA1 transporter-dependent
hepatic secretory pathway [53]. Consistent with this view, αTTP expression enhances α-
TOH secretion in cultured hepatocytes [47,54,55]. The Sec14 nanoreactor concept suggests
an alternative model – αTTP may link heterotypic α-TOH/PtdIns binding or exchange to
generation of a phosphoinositide pool dedicated to biogenesis of α-TOH-rich exocytic
vesicles. This model predicts that compromise of the PtdIns-binding barcode in αTTP will
inactivate the protein. In this regard, the R221W missense substitution, which results in
severe AVED, directly alters the PtdIns-binding barcode. This position corresponds to Sec14
residue K239. This residue helps coordinate binding of the phosphate moiety through which
the Ins headgroup is esterified to the glycerol backbone. Substitutions at this position
specifically compromise PtdIns binding by Sec14 [12,30]. Similarly, the R192H AVED-
associated missense substitution in αTTP corresponds to Sec14 amino acid G210 – a residue
positioned adjacent to core elements of the PtdIns-binding barcode.
Caytaxin & cerebellar ataxia—Cayman-type cerebellar ataxia is a rare autosomal
recessive disorder whose incidence is limited to an isolated population on the Grand
Cayman Island resulting from defects in the brain-specific, Sec14-like presynaptic protein
termed caytaxin. Clinical manifestations include cerebellar hypoplasia, psychomotor
retardation, hypotonia from birth, prominent nonprogressive cerebellar dysfunctions that
manifest through intention tremors, dysarthric speech and a wide-base ataxic gait. This
disease is distinguished from other ataxias by the presence of nystagmus and the lack of
retinal defects [56,57]. Although lipid ligand(s) for caytaxin are unknown, structural
modeling suggests PtdIns lipids are tenable candidates [56,58] – a concept fortified by a
recognizable structural barcode for PtdIns binding [12]. Analyses of Cayman-type ataxic
individuals reveal two polymorphisms. One disrupts an exon–intron boundary, leading to
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truncation of much of the protein, and an S301R missense mutation [56]. Our analyses
project S301 to fall into the helical gate region of the caytaxin Sec14 fold, suggesting gate
dynamics that regulate transitions between open and closed caytaxin conformers might be
compromised. An interesting question for future address is whether compromise of the
putative caytaxin PtdIns-binding barcode inactivates the protein.
Much of what is known about caytaxin is derived from the study of rodent models. Caytaxin
derangements result in a spectrum of motor malfunctions/dystonia in the jittery (ji), hesitant
(jihes), sidewinder (jiswd) and wobbly mice [301], and the well-characterized dystonic (dt) rat
[59]. A battery of electrophysiological and biochemical studies define the olivocerebellar
pathway, particularly in the response of Purkinje cells to climbing fiber projections, as the
point of functional abnormality in the dt rat [60]. The dt rat cerebellar cortex exhibits altered
transcript levels for signaling pathway components that regulate cell-surface signaling,
calcium homeostasis, extracellular matrix and PtdIns signaling [58]. Upregulation of
caytaxin in human prefrontal cortex is also associated with altered calcium homeostasis and
immune system imbalances in schizophrenia [61]. Interestingly, while dt rats normally die
by postnatal day 40, cerebellectomy rescues both ataxia and viability, suggesting that
aberrant cerebellar signaling lies at the root of the observed dysfunctions [62–64].
Caytaxin physically interacts with a number of proteins, including the E3 ubiquitin ligase
CHIP [65], and peptidyl-prolyl isomerase during neuronal differentiation [66]. These
associations suggest caytaxin function may be regulated by its binding to these proteins.
Furthermore, the caytaxin Sec14 domain binds to the kidney-type glutaminase – an enzyme
that converts glutamine to the abundant neurotransmitter glutamate. Caytaxin
overexpression results in the translocation of the enzyme from the cell body to neurite
terminals, and reduces steady-state glutamate levels by inhibiting glutaminase. On this basis,
it is speculated that caytaxin deficiency-associated glutamate elevation underlies the clinical
manifestations of cayman-type cerebellar ataxia [65]. Moreover, overexpression of either
caytaxin or its Sec14-domain alone results in the elongation of processes in MCF-7 cells, as
is the case with overexpression of the caytaxin homologue BNIP-2 [67,68]. Finally, caytaxin
also scaffolds kinesin light chain 1 in cultured hippocampal cells, thereby facilitating
transport of vesicle cargo [68].
Cellular retinaldehyde binding protein & the vertebrate visual cycle—In
vertebrates, light absorption by opsin results in photoisomerization of 11-cis-retinaldehyde
(11-cis-RAL) to all-trans-retinaldehyde (all-trans-RAL). Thus, 11-cis-RAL regeneration is
essential for a sustained vertebrate visual cycle. Detailed description of the vertebrate visual
cycle is beyond the scope of this review; and the reader is referred to detailed reviews on the
subject [69,70]. An important component of 11-cis-RAL regeneration is the Sec14-like
cellular retinal-binding protein (CRALBP) 1. Multiple pathologies are associated with
CRALBP1 dysfunction, including: retinitis pigmentosa, fundus albipunctatus,
Newfoundland rod/cone dystrophy and Bothnia dystrophy. It is suggested that all of these
disorders are manifestations of retinitis punctata albescens (a flecked retinal dystrophy
characterized by early-onset night blindness, uniform white–yellow spots across the fundus
and the progression of macula and retina atrophy resulting in blindness), which is also a
manifestation of CRALBP1 insufficiencies [70,71]. Moreover, mice deficient in CRALBP1
manifest large reductions in rates of rhodopsin regeneration, 11-cis-RAL production, and
dark adaptation after illumination. Unlike the case in humans, photoreceptor degeneration is
not observed [72].
Sec14-like cellular retinal-binding protein 1 is a soluble protein, primarily expressed in
retinal pigment epithelium cells and in Müller cells, but not in their adjacent photoreceptors
[70]. In retinal pigment epithelium cells, CRALBP1 directly bind the 11-cis-retinol (11-cis-
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ROL) formed after the isomerization of all-trans-retinyl ester, or from activated 11-cis-
retinyl esters used as a storage mechanism [73]. CRALBP1 functions primarily to regulate
esterification of 11-cis-ROL [73], and to act as a carrier molecule to assist in the oxidation
of 11-cis-ROL to 11-cis-RAL in the vertebrate visual cycle [74]. CRALBP1 associates with
11-cis-retinol-dehydrogenase (RDH5) in a ternary complex that involves interaction with
ezrin, actin and the PDZ domain of EPB-50. In this fashion, CRALBP1 is hypothesized to
metabolically channel 11-cis-ROL to RDH5 for oxidation [75]. CRALBP1 binds to acidic
phospholipids, and this binding promotes release of bound 11-cis-retinal [76]. It is not yet
clear whether 11-cis-retinal release is mediated by competition for an overlapping binding
site within the CRALBP1 hydrophobic pocket (i.e., in effect a Sec14-like heterotypic lipid
exchange reaction) or whether acidic phospholipid interactions with the protein surface
evoke conformational changes that eject 11-cis-retinal.
Several naturally occurring mutations in CRALBP1 compromise retinoid binding (e.g.,
R151Q and M226K), or enhance its binding (e.g., R234W) [77,78]. In this regard, the
autosomal recessive Bothnia dystrophy presents an interesting case. Pathologies include
night blindness in early childhood and progressive macular/peripheral retinal degeneration
[79,80]. Bothnia dystrophy occurs in one per 3500 births worldwide, with increased
incidence in northern Sweden, primarily as a result of inheritance of the R234W and M226K
variants [79]. The crystal structures of 11-cis-RAL-bound CRALBP1 and the R234W
mutant were recently solved [81]. These studies reveal that R234W further stabilizes bound
11-cis-RAL by increasing packing interactions within the binding cavity. In addition, R234
resides in a conserved basic cleft of CRALBP1. R234 corresponds to Sec14 residue R208,
which helps coordinate PtdIns binding by Sec14 and is a component of the Sec14 structural
barcode for PtdIns binding [12,30].
Although discussions of CRALBP1 are dominated by its involvement in the vertebrate
visual cycle, elevated CRALBP1 levels are associated with altered calcium homeostasis and
immune system imbalances in schizophrenia [61]. CRALBP1 may also represent a human
autoimmune uveitis autoantigen [82], and its status may affect ethanol preference in mice
[83].
Multidomain Sec14-like proteins & disease
The Sec14 superfamily is too large to cover in one review. The distant members of the
superfamily, the BNIP proteins, which primarily function in apoptosis, are reviewed
elsewhere [84,85], and will not be emphasized here. A partial list of multidomain Sec14-like
proteins not emphasized in this article is provided in Table 1. Instead, we focus on a set of
examples relevant to human disease.
Small GTPases of the Rho/Rac/Cdc42 families regulate a number of cellular activities such
as migration, cytoskeleton dynamics, cell cycle progression, gene expression, cell adhesion
and others [86]. These do so by functioning in binary switch mode between GTP- (active)
and GDP-(inactive) bound states. Modular proteins with Sec14-domains include a number
of regulators of small GTPase signaling; in other words, guanine nucleotide exchange
proteins (GEFs) and GTPase-activating proteins (GAPs). Sec14-like domains are also
associated with other enzymatic activities such as protein kinases and protein tyrosine
phosphatases. In these multidomain protein contexts, Sec14 domains are posited to function
as nanoreactors that stimulate ‘on demand’ phosphoinositide synthesis in the immediate
vicinity of the particular catalytic domain of the protein, thereby effecting an efficient
regulation of protein enzymatic activity [13]. The spectrum of diseases caused by
derangements in Sec14-like proteins includes various cancers, neurological disorders,
developmental and trafficking defects. Some outstanding examples are summarized below
and the relevant Sec14-domains often present recognizable PtdIns-binding barcodes.
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RhoGEFs with Sec14 domains—The Dbl family of RhoGEFs is defined by an
approximate 200-residue Dbl homology (DH) domain positioned adjacent to a C-terminal of
an approximate 100-residue plekstrin homology (PH) domain. Of the approximately 70 Dbl-
family RhoGEFs, four (Dbl, Dbs/Ost, Duo/Kalirin and Trio) exhibit Sec14-domains
[84,86,87]. All four RhoGEFs are expressed as multiple slice variants, not all of which
harbor a Sec14 domain, thereby offering mechanisms for differentially regulating the
functional properties and subcellular localization of individual isoforms [88–91].
Dbl—Dbl, the founding member of the Dbl family of RhoGEFs, is represented by at least
four splice variants, three of which contain a Sec14 domain. This domain regulates Dbl
localization and GEF activities [92], and binds PtdIns-3-P, PtdIns-4-P and PtdIns-5-P in
vitro [89]. Oncogenic forms of Dbl exist that exclude the N-terminal 496 residues of the
protein, thereby truncating the Sec14 domain and several spectrin repeats [87,93]. These
oncogenic forms of Dbl influence cell migration, cell polarity and vascularization of
epithelial tissue in murine lens [94]. Dbl-null mice are rather normal phenotypically,
although these do present measurable defects in dendrite elongation [95].
Kalirin/Duo—Kalirin/Duo is a neuronal RhoGEF represented by at least eleven forms, six
of which contain a Sec14 domain (Kalirin-SOLO, 4, 7, 8, 9 and 12) [96–98]. Full-length
kalirin (Kalirin-12) is a complex protein that exhibits a Sec14-like domain, nine spectrin-like
repeats, two DH, two PH, two SH3, one immunoglobin, one fibronectin III and one Ser/Thr
protein kinase-like domain (Figure 5) [99]. The isolated Kalirin Sec14-domain is reported to
bind phosphoinositides based on crude lipid blot assays [98]. Kalirin nullizygous mice show
cognitive and working memory deficiencies associated with reduced neuronal spine
densities and abnormal spine morphologies [100]. These neuronal morphology defects are
also manifested in ex vivo culture [101]. In addition, Kalirin is implicated as a genetic risk
factor for ischemic stroke [102], coronary artery disease [103], Alzheimer’s disease [104]
and schizophrenia [100,105].
The predominant Kalirin, Kalirin-7, is an important regulator of dendritic spine development
and functional plasticity [106,107]. NMDA receptor activation in pyramidal neurons induces
a CaMkII-dependent phosphorylation of Kalirin-7 on its Sec14-domain. This
phosphorylation stimulates Kalirin-7 GEF activity, and elicits enlargement of neuronal
spines via enhanced activation of Rac1 [108]. Moreover, the Kalirin-7 Sec14-domain may
also interact with GBγ subunits of heterotrimeric G-proteins [109]. Although it is clear that
the Sec14 domain is important for Kalirin-7 function, the mechanisms for how the Sec14
domain interfaces with other Kalirin-7 domains is not understood. As the Sec14 domain is
implicated as a negative regulators of other Dbl family members [88], and phosphorylation
of the Sec14 domain promotes GEF activity, a negative regulatory role is a distinct
possibility [108]. Whether lipid binding is involved in such a circuit remains to be
determined. Moreover, variants produced from an alternative translation start site truncate
the Sec14 domain and the first four spectrin repeats (Δ-Kalirin-7) exhibit distinct properties
with regard to regulation of endocytosis, solubility, oligomerization state, cytoskeleton
binding and subcellular localization [98].
Trio—Trio contains a Sec14 domain and eight to nine spectrin repeats linked to two DH
domains, two PH domains, two SH3 modules, one immunoglobin domain and one Ser/Thr
kinase catalytic domain (Figure 5) [87,110]. Trio is represented by at least six isoforms, five
of which contain a Sec14 domain [91]. Trio nullizygous mice fail in embryonic development
with deranged organization of neural tissues and defects in fetal skeletal muscle [111].
Recent studies implicate Trio in netrin-1/deleted in colorectal cancer (DCC)-dependent axon
guidance through its ability to activate Rac1 [110], and its expression is associated with
invasive tumor growth and rapid tumor cell proliferation in bladder cancer [112]. Moreover,
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genome-wide association studies also link Trio expression to esophageal squamous cell
carcinoma [113]. The short Solo/Trio8 isoform (contains the Sec14 domain), which is
primarily expressed in Purkinje cells, localizes to endosomes where it activates Rho
GTPases and promotes neurite elongation in developing Purkinje cells. The Sec14 domain is
suggested to contribute to endosomal localization of this isoform [114]. Human Trio also
potentiates the nerve growth factor pathway for RhoG- and Rac1-dependent neurite
outgrowth in PC12 cells. However, the Sec14 domain is dispensable for the neurite-
promoting activity of Trio [115].
Dbs—The Dbs/Ost RhoGEF is a proto-oncogene that modulates cell motility in human-
derived breast epithelial cells via activation of Cdc42 and Rac1 [116]. The protein consists
of an N-terminal Sec14 domain, two spectrin repeats, a DH domain, a PH domain and an
SH3 domain (Figure 5) [88]. The purified Dbs Sec14 domain binds a variety of
phosphoinositides in crude lipid blot assays [88], and the Sec14 domain is responsible for
directing Dbs subcellular localization so that it can interact with its primary substrate Cdc42
[89]. Sec14-domain activities are not simple as this module also inhibits Dbs transforming
activity by interacting with the PH domain and regulating subcellular localization [88].
Whether this Sec14/PH-domain interaction is regulated by lipid binding remains to be
determined.
RhoGAPs—The RhoGAP family is populous – counting in excess of 70 members. Of
those, p50RhoGAP/Cdc42GAP and BPGAP1 are similar proteins that exhibit N-terminal
Sec14-domains appended to RhoGAP domains by proline-rich linker domains (Figure 5)
[117].
CDC42GAP/p50RhoGAP—Mice deficient for Cdc42GAP exhibit multiple premature
aging defects including reduction in body mass, loss of subdermal adipose, muscular
atrophy, osteoporosis and delayed wound healing [118], and present enhanced rates of c-Jun
N-terminal kinase (JNK)-mediated basal apoptosis [119]. As may be expected, Cdc42GAP-
deficient murine embryonic fibroblasts display elevated Cdc42 activity, and these cells are
prone to spontaneous formation of filipodia with defects in directional migration [120].
Cdc42GAP derangements are implicated in human disorders such as Waldenstrom
macroglobulinemia [121] and human chronic myeloid leukemia [122]. CDC42GAP is also
suggested to be a counter-regulator of tubule formation, forecasting a role in angiogenesis
[123].
The Sec14-like domain is responsible for localization of Cdc42GAP to endosomes as
evidenced by the fact that missense substitutions in the presumptive Sec14-like lipid-binding
pocket result in Cdc42GAP mislocalization. In that regard, Cdc42GAP interacts with the
Rab11 GTPase, suggesting a link between Rab and Rho GTPases and endosome dynamics
[124]. Cdc42GAP exists in an autoinhibited state that is controlled in part by intermolecular
interactions between amino acids 1–48 and 169–197, which reside in the Sec14-like domain.
Interaction with the prenyl group of small GTPases promotes the release of autoinhibition
[125].
Neurofibromin RasGAPs—Neurofibromin (NF)-1 encodes for a 2818-residue RasGAP
that is homologous to the yeast RasGAPs, Ira1 and Ira2 [126,127]. Defects in NF-1 result in
the progressive, autosomal dominant disorder, neurofibromatosis type 1, affecting one in
3500 individuals worldwide. The disease manifests through multiple brown skin macules
(café-au-lait spots), intertriginous freckling, iris hamartoma (Lisch nodules) and learning
disabilities. NF1 patients are also at a higher risk for optical gliomas and neurofibromas
[128,129]. NF-1 primarily regulates p21-Ras-GTP levels, thereby modulating downstream
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cascades including Ras–MAPK and Akt–mTOR pathways. Loss of NF-1 activity
deregulates of these proproliferative pathways and inhibits apoptosis [130].
NF-1 has three discrete domains: the RasGAP catalytic module [131], the Sec14-like
domain [132] and a PH domain [127]. Several other domains have recently been defined
largely on the basis of bioinformatic analyses (Figure 5) [133]. A number of missense
substitutions elicit NF1 loss-of-function phenotypes without destabilizing the protein
[134,135]. Several of these substitutions map to the Sec14 domain, thereby demonstrating
the functional importance of this domain for NF-1 biological activity. A series of these
disease-associated mutations affect residues that either comprise, or flank, the hinge domain
of Sec14-like proteins. These substitutions likely interfere with conformational transitions of
the helix, which gates the hydrophobic pocket [136]. In addition, a tandem repeat mutation
identified in a neurofibromatosis patient with Noonan’s disease duplicates a linker region
between the NF1 Sec14 and PH domains, indicating that interdomain communications
between the Sec14, PH and RasGAP domains are required for operative NF1 activity [127].
Sec14-like protein tyrosine phosphatase—A Sec14 module is incorporated into the
68 kDa, cytoplasmic, protein-tyrosine phosphatase MEG2/PTPN9 [137–139]. In vitro
experiments suggest that PTP-MEG2 binds PtdIns(3,5)P2, PtdIns(4,5)P2, PtdIns(3,4,5)P3
and phosphatidylserine [137,140]. Thus, interaction of the Sec14 domain with lipids may
control both MEG2 localization and phosphatase activity. Murine MEG2 is highly expressed
in the brain, liver, kidneys and testes. Mice deficient for MEG2 exhibit embryonic lethality
with a penetrance of more than 90% with hemorrhage, neural tube defects, decreased size,
immunodeficiency and abnormal bone development. It is suggested that many of these
dysfunctions result from defects in secretory processes [141]. MEG2 targets the cytoplasmic
face of secretory vesicles in a Sec14 domain-dependent manner, where it promotes vesicle
fusion by dephosphorylating (and activating) the N-ethylmaleimide-sensitive factor essential
for resolving cis-SNARE-pins [142]. While missense substitutions projected to compromise
PtdIns binding do not prevent MEG2 association with vesicles, these substitutions do
inactivate the protein for stimulating vesicular fusion [137,143]. The available data suggest
the MEG2 Sec14 domain executes functions in addition to membrane targeting.
Type 1 START-like PITPs as molecules
As is the case for Sec14-like PITPs, the origins of START-like PITPs are rooted deep in
eukaryotic evolution. Database searches identify candidate type 1 PITP-like proteins in
protists with highly streamlined genomes (e.g., Giardia, Enterocytozoon and
Encephalitozoon). As we highlight PITPs in the context of mammalian disease in this
review, we focus primarily on what we know about the mammalian versions of these
proteins. There are three mammalian START-like type 1 PITPs (PITPα, RdgBβ and PITPβ).
Essentially nothing is known about RdgBβ and we will ignore it for the remainder of this
review. Instead, we focus on the homologous PITPα and PITPβ - both of which are classical
PITPs. These proteins are encoded by distinct genes, yet share 77% identity at the primary
sequence level. PITPβ is expressed as two splice variants (termed canonical and alternative
on a historical basis), which differ only in the extreme C-terminal primary sequence of the
protein [36,144,145]. Zebrafish (Danio rerio) also express a mammalian-like cohort of type
1 PITPs with the addition of a unique PITPβ-like version designated PITPγ. The type 1 PITP
roster extends to interesting details of type 1 PITP diversity – in other words, zebrafish
execute precisely the same exon-skipping splicing event as do mammals in generating the
canonical and alternative PITPβ splice variants [37].
Crystal structures for both PITPα and PITPβ are available, and multiple structural models
for PITPα have been solved (Figure 6). These include high resolution structures for PtdCho-
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bound and phospholipid-free forms [20,146], and a lower resolution structure for the PtdIns-
bound form [147]. As previously indicated, type 1 PITPs are structurally unrelated to Sec14-
like PITPs and are characterized by a START structural fold that forms a single large lipid-
binding cavity. Unlike the case for Sec14-like PITPs, PtdIns and PtdCho assume very
similar poses within the type 1 PITP lipid-binding cavity (Figure 6). The type 1 PITP
strategy for phospholipid binding suggests these proteins may not operate in a Sec14-like
nanoreactor/PtdIns-presentation mode. However, genetic data identify residues Ser25 and
Pro78 as being specifically required for PtdIns-binding/transfer by PITPα [20] – even
though neither residue uniquely contacts PtdIns, or influences other residues that do so, in
the holo-PITPα structure. The existence of such enigmatic ligand-specific binding/transfer
mutants suggests that PtdCho and PtdIns trajectories during lipid exchange are different in
type 1 PITPs, but ultimately converge on similar poses in the closed conformer. Indeed, type
1 PITPs rescue both cell viability and phosphoinositide production in yeast devoid of Sec14.
As yeast membranes are rich in PtdIns (20 mol%), these data indicate type 1 PITPs can
function in a Sec14-like nanoreactor/PtdIns-presentation mode [35,36]. Whether these do so
in the PtdIns-poor mammalian cell (PtdIns represents 5 mol% of bulk phospholipid) is
difficult to demonstrate, yet structural studies suggest that the apo-PITPα conformer displays
an open channel, which provides access to the headgroup binding region. This channel
provides a path via which a lipid kinase could potentially access a PITP-bound PtdIns
headgroup [146]. Such a mechanism requires productive PITP-PtdIns kinase interactions to
occur during the interfacial lipid exchange reaction. This concept is consistent with
nanoreactor/PtdIns-presentation modes of action.
The structural studies also suggest how type 1 PITPs interact with membrane surfaces. Type
1 PITPs present a loop with adjacent Trp residues (Trp203 and Trp204 in PITPα) and it is
reported that compromise of this Trp–Trp motif inactivates the PITP – presumably by
compromising PITP interaction with membranes [147]. This is a controversial issue as other
studies, while demonstrating a requirement for this motif in the more stable association of
PITPβ with Golgi membranes in vivo, nonetheless demonstrate the motif is neither important
for the types of transient membrane interactions that accompany lipid exchange reactions
nor for biological function in a vertebrate context [37,144].
Cellular functions
Despite the similarity between PITPα and PITPβ, the proteins exhibit important differences,
including PITPα being localized to the cytosol/nucleus while PITPβ targets the TGN; PITPβ
is able to bind/transfer the ceramide-based phospholipid (PL) sphingomyelin, in addition to
the glycerol-PLs PtdIns and PtdCho, while PITPα only binds/transfers PtdIns and PtdCho.
From a functional perspective, PITPβ appears to execute important housekeeping function(s)
in the face of robust PITPα expression [148], while PITPα is not essential for cell viability.
As discussed in detail below, PITPα nullizygosity results in neonatal lethality, even though
normal levels of PITPβ are expressed in the nullizygotes.
Remarkably little is known about the cellular functions of type 1 PITPs. Data from
permeabilized cell systems report PITPα stimulates Ca2+-activated secretory granule
exocytosis [149], secretory vesicle and immature granule budding from hepatocyte and
neuroendocrine TGN [150] and plasma membrane receptor/G-protein-coupled
phosphoinositide hydrolysis by phospholipase C (PLC) [151]. PITPα requirements for
agonist-stimulated phosphoinositide synthesis are recorded whether signaling occurs via
receptor or nonreceptor tyrosine kinases, or through PLCβ or PLCγ1 [152,153]. Using a
more physiological system, silencing experiments suggest a cellular role for mammalian
PITPβ in regulating nuclear envelope morphology and retrograde membrane trafficking
from cis-Golgi membranes to the endoplasmic reticulum [154]. In the following section, we
review functional studies of vertebrate type 1 PITPs with murine models as primary focus.
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Both the congruence and the dissonance between cellular studies and animal studies of type
1 PITPs are discussed.
Vertebrate models for type 1 PITP-associated disease
Precisely how type 1 PITP biochemical properties translate to biological activity of the
individual proteins remains to be determined. The RdgBβ remains uncharacterized, and only
recently have insights in vertebrate PITPβ function been forthcoming [37,154]. However, it
is clear that PITPα, at least, is essential for the viability of vertebrate organisms including
mammals. Our understanding of the physiological consequences that accompany impaired
PITPα functionality derive from analyses of a series of mouse lines with graded reductions
in PITPα activity. Hypomorphic lines include the vibrator homozygous mice (vb/vb) and vb/
null heterozygous mice [155–157], which express 20 and 10% of wild-type levels of wild-
type PITPα, respectively. The vb allele is the result of a serendipitous insertion of an IAP
retrotransposon into an intronic region of the pitpα structural gene, thereby reducing the
efficiency with which the cognate pre-mRNA is processed [155,156].
There are currently two categories of what are operationally considered to represent pitpα
null alleles. One is an engineered deletion that eliminates two exons encoding essential
functional elements of the protein. The second is an insertion of a recombinant
retrotransposon, which harbors splice-trap activity and interrupts PITPα mRNA translation
without deleting any portion of the structural gene. Mice homozygous for either the deletion
allele or the splice-trap insertion fail to produce detectable amounts of PITPα protein and
exhibit indistinguishable phenotypes [158]. Most of the detailed characterizations executed
to date involve mice homozygous for the deletion allele.
PITPα & neurological disease
PITPα is produced in most (if not all) cells, but it is particularly highly expressed in brain
and cerebellum. In the adult rat, PITPα is produced most robustly in cerebellar Purkinje
neurons and granule cells [159–161]. Consistent with these expression data, murine model
systems report an important role for PITPα in maintaining integrity of the spinocerebellar
system. PITPα null (pitpα0/0) and hypomorphic mice exhibit striking neurological defects –
the severities of which are proportional to the level of PITPα expressed [155,157,158].
The vb mouse line takes its name from the rapid whole-body tremor observed in vb/vb
homozygotes that reflects a progressive, and ultimately fatal, neurodegenerative disease.
Genetic modifiers strongly affect the lifespan of vb/vb homozygotes. In the inbred C57/B6
background, these hypomorphs live for 31–35 days after birth while in outbred, or even
other inbred, backgrounds lifespans of up to 6 months are recorded [155]. One such genetic
modifier operates at the level of improving ‘read-through’ of the IAP element that defines
the vb insertion mutation, thereby elevating both the levels of mature PITPα mRNA and
wild-type protein produced. The net result is that the lifespan is increased [162].
By contrast, pitpα0/0 mice are born at the expected Mendelian frequencies but usually expire
within several days of birth. In rare cases, the pitpα0/0 homozygotes can persist for 10–13
days after birth. The inability of the nullizygotes to thrive is hallmarked by obvious tremor
and impaired motor capacity [158]. Unlike the case of vb/vb mice, the abbreviated lifespan
of pitpα0/0 homozygotes is independent of genetic background and is accompanied by two
additional signature pathologies – hypoglycemia and intestinal chylomicron retention
disease (CRD) [157,158]. These syndromes are addressed in subsequent sections and, as
discussed later, contribute to the rate of onset of neurological disease in PITPα-deficient
animals.
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The neurodegenerative disease course of the vb mouse is classified into three phases. Phase I
describes the ‘true vibrator’ phenotype defined by fine, high-frequency postural tremors that
become apparent approximately 15 days after the birth of pitpαvb/vb homozygotes. Phase I
postural tremors are reminiscent of the enhanced physiological tremors encountered in
clinical settings [155,163]. While the etiology of enhanced physiological tremors in humans
is not known, such tremors often present as a symptom of hyperthyroidism or metabolic
dysfunction such as hypoglycemia and liver disease. In that regard, pitpα0/0 mice also
display hepatic steatosis and severe hypoglycemia (see below; [158]).
PITPα null mice do not present Phase I phenotypes. Instead, Phase II symptoms are detected
from the outset, indicating neuronal damage even at the earliest stages of postnatal life
[155,157,158]. Phase II is marked by ataxia and action tremors. The coarse intention tremor
is superimposed on the animal’s voluntary movements. These neurological symptoms are
distinct, and not simply progressive, from Phase I symptoms. Furthermore, Phase II presents
with clear anatomical signs of degeneration. Neurons in the lumbar and cervical spinal cord
and in the cerebellum are vacuolated, aponecrotic and display distended endoplasmic
reticulum (ER; see later). In genetic backgrounds where vb mice are reasonably long lived
(5–6 months), the disease progresses to a severe cerebellar atrophy [155]. For these reasons,
Phase II defines the ‘degenerative’ phase. In the inbred C57/B6 background, Phase II
persists until hours before the animal perishes. The basic presentation of Phase II disease
resembles the symptoms associated with clinical cases of stroke, inherited
neurodegenerative disorders and multiple sclerosis [164–166].
The terminal stages of PITPα insufficiency define Phase III disease characterized by loss of
consciousness, decreased motor tone and fasciculations, and a progressive ascending motor
paralysis that ultimately leads to asphyxiation. For C57/B6 animals, Phase III signals
imminent death (within hours) and appears at approximately 31–33 days postnatal in the
case of vb/vb homozygotes.
Anatomy of neurodegenerative disease in PITPα-deficient mice
PITPα null mice exhibit robust inf lammation and demyelination in the spinal cord [158].
There are clear reductions in white matter in the cervical, thoracic and lumbar spinal cord,
and damaged neurons are observed at the white and gray matter interface. Inflammation is
evident over the entire length of the spinal cord, but is most striking in the ventral horn, in
other words, where motor neuron cell bodies are located. Many of the neuronal cell bodies
in the ventral horn present the vacuolation and low cytoplasmic content typical of
aponecrosis – a form of cell death associated with critically low cellular energy charge.
Indeed, measurements of ATP:ADP ratios indicate that pitpα0/0 cerebellum and liver are
under significant energy stress while the brain does not. Consistent with the widespread
aponecrosis occurring in those regions, mast cells and macrophages infiltrate into the
perivascular matrix and vessels, as well as the perivascular tissue, indicating breach of
blood–brain barrier integrity. Extensive defects in myelination are obvious in both white and
gray matter regions of dorsal spinal columns, and are accompanied by axonal swelling and
neuropil degeneration. Another striking property of pitpα0/0 brain is the reactive gliosis
evident throughout the cerebellum – the organ is inundated with activated microglia. Again,
vacuolations of smooth ER are prevalent in cerebellar neurons of pitpα0/0 mice [158]. The
fulminating spinocerebellar inflammatory disease indicates regulated exocytic pathways
associated with the activities of inflammatory cells (e.g., mast cells) are not strongly
compromised in the null animal. The results from mouse studies are incongruent with those
obtained from permeabilized cell system, which suggest that PITPα is required for such
regulated exocytic events [149,158]. These data are consistent with the report that pitpα0/0
embryonic stem cells differentiated ex vivo produce mast cells capable fully of executing the
agonist-stimulated compound exocytosis that is a distinguishing property of these
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inflammatory cells [148]. Synaptic performance is also unperturbed in pitpα0/0 neurons
under multiple testing regimes [158]. This is a surprising result given that the synaptic
vesicle cycle is a high-capacity phosphoinositide-utilizing system [4].
It is difficult to interpret whether the spinocerebellar degeneration observed in pitpα0/0 mice
is a primary phenotype or a secondary consequence of the glucose homeostatic and CRD
defects that define major phenotypes of the null condition. The substantially postnatal
development of the cerebellum dictates a robust proliferative program for cerebellar
neurons. Engagement of such a vigorous cell growth program, in the face of severe
hypoglycemic circumstances, must soon come to a critical point where proliferation can no
longer be sustained in an inadequate physiological environment. Such a catastrophic
developmental failure is expected to result in manifest necrosis and induction of a
fulminating inflammatory response. These predictions are fulfilled by the cerebellar
inflammatory disease of PITPα-deficient mice. With regard to the spinal cord, affected
motor neurons are extraordinarily large cells, and it is likely these are especially sensitive to
environmental insult. That the spinocerebellar degeneration is, at least in part, caused by a
hostile physiological environment is further indicated by demonstrations that pitpα0/0
cerebellar granule cells, and dorsal root ganglia from spinal cord, are not intrinsically fragile
when cultured ex vivo. Moreover, titration experiments indicate these pitpα0/0 neurons are
not overly sensitive to reduced trophic factor availability relative to wild-type neurons [158].
To determine the degree of interdependence among the phenotypes observed in pitpα0/0
animals, Alb et al. generated an allelic series of mice in which levels of wild-type PITPα
protein are graded across a broad functional range. These studies establish that the threshold
levels of PITPα activity sufficient to relieve CRD and hypoglycemia remain inadequate for
sparing spinocerebellar degeneration; although onset of neurodegenerative disease is
significantly delayed in the absence of hypoglycemia and CRD [157]. The collective data
indicate that spinocerebellar disease is an intrinsic pathology of PITPα-deficient mice.
Cell nonautonomous mechanisms for PITPα-dependent neuroprotection
The neurodegenerative pathologies associated with PITPα insufficiencies suggest a
prosurvival/antiapoptotic role for PITPα at the cellular level. Such an activity can be
formally executed in a cell nonautonomous manner, in other words, where PITPα function is
not required in neurons but must be present in nonneuronal support cells that nourish
neurons. Alternatively, PITPα could exert its functions in a cell autonomous manner where
protein activity is required in the neurons themselves. The available information suggests
both mechanisms may be relevant. With regard to cell nonautonomous mechanisms of
PITPα action, cells overexpressing PITPα are reported to secrete an as yet uncharacterized
trophic factor that promotes neuronal survival ex vivo [167]. Presumably, genetic ablation of
PITPα function interferes with production of this factor, thereby contributing to neuronal
fragility in PITPα-deficient animals. A chemical identification of such PITPα-regulated
trophic factors would constitute an important advance in our understanding of how PITPα
helps confer neuroprotection to the spinocerebellar system. A cell nonautonomous
mechanism of this nature forecasts that targeted ablation of PITPα function in neuronal
support cells, such as glia and/or oligodendrocytes, will recapitulate at least some features of
the spinocerebellar inflammatory disease recorded for pitpα0/0 mice.
PITPα & cell autonomous signaling
PITPα is identified as an essential component in promoting signaling of plasma membrane-
localized receptor tyrosine kinases that register extracellular signals and transmit the
information to downstream effector pathways. Two such circuits feature prominently in
discussions of intracellular mechanisms for PITPα function. First, PITPα was purified as a
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cytosolic factor required for EGFR signaling in a system where the ligand-dependent EGFR
stimulation of PLCγ was reconstituted in permeabilized cells [153]. In this system, PITPα is
posited to deliver PtdIns to the signaling plasma membrane so that a phosphoinositide pool
required for forward EGFR signaling is generated by PtdIns 4-OH and PtdIns-4-phosphate
5-OH kinases. Second, in an analogous mechanism, PITPα is reported to be obligatorily
required for signaling via the netrin receptor DCC [152]. Netrins are secreted guidance cues
that promote axon elongation and direct pathfinding during neuronal development and are
essential for the proper formation of major commissures in the brain and spinal chord
[168,169]. In both studies, the major conclusion is that PITPα binds activated receptor and,
in this fashion, brings PtdIns from the ER to the site of receptor–ligand engagement. This
supply activity is then posited to stimulate local production of phosphoinositide and, in turn,
downstream signaling [152,153]. In a related scenario, PITPα is reported as fueling a
phosphoinositide-3-OH kinase signaling pathway required for elongation of cortical neurons
on specific extracellular matrices ex vivo [170].
The parallel logic proposed for how PITPα promotes EGFR and DCC signaling via cell
autonomous mechanisms is attractive because it makes strong predictions regarding how
null cells should behave in a physiological context. From the perspective of neuronal
development, loss of an amplifying factor such as PITPα should impair spinal cord and brain
structures whose development is netrin- or DCC-dependent. Some properties of the pitpα0/0
mouse are superficially consistent with such a model [157,158]. It is a tenable hypothesis
that comprehensive defects in axon guidance would lead to extensive neuronal cell death by
apoptosis and, in the case of a hypoglycemic animal, aponecrosis, as is observed in pitpα0/0
mice. However, there are discrepancies between the central predictions of the proposed
model for functional coupling of PITPα with DCC and in vivo experimental results.
Significant defects in netrin signaling result in obvious structural abnormalities of the brain,
including deranged development of the anterior and hippocampal commissures, and the
corpus callosum [169]. However, the pitpα0/0 brain does not present such obvious
derangements and, moreover, the pitpα0/0 cortex is not significantly smaller than its wild-
type counterpart [157]. The idea that PITPα obligatorily promotes DCC signaling is also
inconsistent with the properties of the kanga mouse, a mutant animal with a spontaneous and
clean deletion of the essential PITPα-binding domain in the DCC cytosolic tail [152,171].
While this mouse exhibits an abnormal gait, and the kanga brain recapitulates the structural
defects observed in netrin-deficient brain, the mouse nonetheless survives to adulthood and
is fertile [171]. By contrast, DCC null mice present embryonic lethal phenotypes [168]. The
kanga and pitpα0/0 phenotypes are not consistent with a strong compromise of DCC function
in the absence of interaction with PITPα.
The EGFR-PITPα forward signaling paradigm formulated from permeabilized cell studies
also fails to translate cleanly to authentic physiological contexts. As an active EGFR
signaling network initiates a transcriptional response that promotes cellular survival and
proliferation [172], loss of a factor that increases the gain on forward-signaling (i.e., PITPα)
should compromise cell vigor and proliferative capacity. However, pitpα0/0 murine
embryonic stem cells retain their tumorigenicity when introduced into nude mice. This is not
an outcome obviously consistent with overt growth factor signaling defects. Moreover,
PITPα hypomorphic animals do not present obvious waved phenotypes that result from
defective hair follicle development in mice with even partial defects in EGFR signaling
[155,157,173]. The corresponding null phenotypes differ as well. EGFR nullizygosity
generally results in embryonic lethality. In some genetic backgrounds, the knockout mice
are born alive, but expire within the first postnatal week, and exhibit multiple symptoms of
delayed epithelial development. Those ‘escapers’ show defective eyelid development,
deranged terminal differentiation of the epidermis and hair follicles, and loss of structural
integrity of intestine – as evidenced by shortening of the organ, reduced numbers of villi and
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hemorrhage. Moreover, EGFR deficiency leads to respiratory failure as a consequence of
structurally immature alveoli [174,175]. No such defects are reported for pitpα0/0 mice.
In summary, the in vivo data are not consistent with simple models invoking obligatory roles
for PITPα in forward DCC or EGFR signaling. It remains formally possible that a PITPα
involvement in promoting DCC or EGFR signaling is subtle, or that this requirement
exhibits an unexpected, and as yet unidentified, tissue-specificity. The idea that significant
compensatory mechanisms are engaged in the face of chronic PITPα deficiency cannot yet
be dismissed. However, the counter view that PITPα does not promote forward EGFR or
DCC signaling must be considered as well. These issues frame a set of important questions
for future analysis.
PITPα insufficiencies & chylomicron retention disease
A major phenotype associated with pitpα0/0 homozygosity is failure of such neonates to
thrive, in other words, mutant animals achieve only a half to a third of the mass of PITPα+/+
and PITPα0/+ heterozygous littermates within the first postnatal week. The phenotype is
manifested even though the null animals nurse reasonably effectively – as evidenced by
direct observation of the act and analysis of stomach contents, and by the fact that pitpα0/0
nullizygotes are not dehydrated. Whole-body chemical analyses demonstrate the reduced
body mass is substantially accounted for by a pathologically low body fat content, a
deficiency confirmed by the virtual absence of axillary and inguinal fat pads in nullizygotes
[158]. These homeostatic pathologies stem from inefficient processing of dietary fat by the
nullizygous animals, and available data report that the homeostatic deficiencies are
manifestations of functional derangements in pitpα0/0 intestine and liver.
Two lines of evidence indicate that pitpα0/0 neonates cannot effectively absorb dietary fat
across the intestinal epithelium. First, enterocytes of the pitpα0/0 duodenum stain unusually
heavily with lipophilic agents (Figure 7) and this property disappears upon prolonged
fasting. Second, electron microscopy reveals dramatic accumulations of lipid bodies in the
lumen of the enterocyte ER of pitpα0/0 neonates – an accretion accompanied by dilations of
smooth ER (Figure 7). These accumulated lipid bodies resemble maturing chylomicrons, in
effect the lipoprotein transport units that ferry dietary fat via the enterocyte secretory
pathway for discharge into the circulation and disbursement throughout the body. Taken
together, the morphological data indicate that pitpα0/0 enterocytes are competent for the
hydrolysis of dietary triglycerides (TGs) into fatty acids and monoacylglycerols, the
transport of these hydrolytic products into the enterocyte ER lumen and the reconstitution of
these products into TGs for subsequent packaging into what we loosely term as chylomicron
precursors. The point of failure is in inefficient export of chylomicron precursors from the
enterocyte ER, via the secretory pathway, and into the circulation.
Consistent with this basic scenario, pitpα0/0 neonates present dramatic reductions in levels of
circulating postprandial TG and brain α-tocopherol (another lipophilic molecule whose
transport across the enterocyte into the circulation requires a functional chylomicron
pathway). The collective data suggest a PITPα involvement in the packaging of TG cores
into functional chylomicron carriers for transport from the enterocyte ER. Defects in this
process hallmark CRD. The threshold requirement for PITPα in chylomicron transport is
low given that an 80% reduction in PITPα expression is insufficient to induce CRD in mice,
but a more than 90% reduction in PITPα load does [157]. The defect is also tissue-
autonomous as reconstitution of intestine-specific PITPα expression in the null animal
rescues the CRD [157].
PITPα involvements in ER functions are unanticipated, as all discussions of functional
mechanisms focus on roles for PITPα in modulating plasma membrane signaling circuits
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(see previous sections). It remains to be established whether PITPα is directly, or more
indirectly, involved in chylomicron biogenesis. Indirect models would include regulation of
chylomicron maturation from a remote compartment via some PITPα-dependent signaling
pathway. Some concepts for how PITPα may directly interface with chylomicron trafficking
from the ER are suggested by recent studies on the etiology of human CRD, such as
Anderson’s disease and hyperbetalipoproteinemia. These CRD syndromes are autosomal
recessive disorders characterized by fat malabsorption and pediatric failure to thrive [176].
The associated human duodenal steatosis, when coupled with other aspects of human CRD
symptomology, is similar to the CRD and associated phenotypes of pitpα0/0 mice. Positional
cloning analyses demonstrate that one mechanism for inherited human CRD stems from
autosomal recessive loss-of-function mutations in the SARA2 GTPase [177]. SARA2 is the
product of the SAR1B gene, and represents one of the two members of the Sar1-like small
GTPases expressed in humans.
The Sar1-like GTPases are conserved from yeast to man and these are essential for
nucleation of COPII vesicle formation at organized regions of the ER membrane surface
termed ER exit sites [178]. The specific requirement for SARA2/Sar1b in chylomicron
packaging for transport from the enterocyte ER is interesting because these lipoprotein
cargos are much larger than typical COPII transport vesicles. One interpretation of the
genetic data is that SARA2/Sar1b is a privileged GTPase dedicated to formation of atypical
COPII vesicles designed to carry unusually large cargos. It follows that PITPα is a similarly
privileged component of such a specialized COPII vesicle biogenic pathway [158]. Perhaps
PITPα regulates an ER pool of PtdIns-4-phosphate required for biogenesis of a subclass of
COPII vesicles dedicated to transport of mega-cargos such as chylomicrons. This proposal is
supported by the demonstration that mice expressing wild-type amounts of a PtdIns-binding-
defective mutant of PITPα as the sole source of the protein are indistinguishable from
pitpα0/0 animals, including with regard to severity of CRD [157]. While the concept that
PITPα modulates an ER pool of phosphoinositide departs from dogmatic views that
phosphoinositides are localized exclusively to intracellular compartments in the distal
secretory pathway [179], recent findings that Sar1-mediated ER exit site formation is
regulated by PtdIns-4-phosphate bolster this idea [180].
pitpα0/0 mice & hepatic steatosis
The intestine and liver deploy similar strategies for the processing and export of lipoprotein
cargos from the ER into distal compartments of the secretory pathway and, ultimately, into
the circulation. In that regard, the pitpα0/0 liver also presents extensive microvesicular
steatosis as evidenced by the unusually enhanced staining with osmium or the lipophilic dye
Oil Red O (Figure 7) [158]. Electron microscopic and lipidomic analyses confirm dramatic
intracellular accretion of neutral lipid in the organ. However, in this case, a large fraction of
the lipid accumulates in cytosolic lipid droplets and, remarkably, in lipid droplets that
populate the nuclear matrix of pitpα0/0 hepatocytes (Figure 7) [158]. While vb/vb mice do
not present such dramatic symptoms of hepatic steatosis, lipidomic analyses report that the
livers of these animals also exhibit elevated levels of neutral lipid [181].
The intrahepatic lipid accumulation is not the result of elevated lipid biosynthesis; the
expression of key fatty acid and lipid biosynthetic enzymes is not enhanced. Whether the
pitpα0/0 liver is defective in lipoprotein trafficking from the ER, as is the case in intestine,
remains to be investigated. However, there is no doubt that an important aspect of lipid
homeostasis is deranged in pitpα0/0 liver, and this deficiency has interesting consequences
for outcomes of intestine-specific reconstitution strategies directed at alleviating CRD.
Rescue of CRD by intestine-specific expression of PITPα, in otherwise pitpα0/0 mice, levies
surprisingly modest improvements in the systemic TG and fat storage defects that
characterize this animal. The basis for the inefficient translation of a functionally
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reconstituted intestine to more normal circulating lipoprotein levels appears to rest with
enhanced accretion of lipid in the pitpα0/0 liver of such animals. We presently consider the
amplified accretion to reflect enhanced lipid flow into a dysfunctional liver that cannot
adequately process circulating lipoproteins [157]. The increased import is presumably driven
by a now functional intestine that efficiently secretes chylomicrons into the circulation of the
otherwise pitpα0/0 mouse.
PITPα: is there a link between Ins nutrition & lipoprotein metabolism
There is an old literature associating nutritional deprivation of Ins with defective lipid
clearance from rodent liver and intestine. Rats fed a fatty diet accumulate triacylglycerides
and cholesterol in the liver when myoinositol is withheld from the diet [182–184]. This
accumulation of neutral lipid is the result of defective mobilization of hepatic TGs
[185,186]. In the Mongolian gerbil model, myoinositol starvation resulted in accumulation
of lipid in the small intestine [187] – a phenotype associated with qualitative changes in the
fatty acid composition of enteric phospholipids [188,189]. Notably, this condition was also
marked by significantly decreased levels of circulating lipoprotein [190] – a deficit that was
established as the consequence of inefficient transport of lipid across the intestine [191].
While these observations were taken as evidence for an involvement of PtdIns metabolism
with lipid transport across the intestine [191], no underlying mechanism for the Ins effect
has yet been described. The intestinal and hepatic steatosis that characterizes pitpα0/0 mice
broadly recapitulates the effects of inositol deprivation in rodents. It is now an attractive
proposition that Ins deprivation and functional ablation of PITPα share an underlying
mechanism for provoking intestinal, and perhaps hepatic, steatosis. In other words,
phosphoinositides play an important role in the packaging of unusual cargoes such as
chylomicrons, and other lipoprotein particles for transport from the ER to late stages of the
secretory pathway. This hypothesis raises the interesting possibility that PITPα sets the
efficiency for lipoprotein assembly in intestine and liver and therefore determines the
capacity for lipid clearance in liver and intestine.
PITPα & the pancreas
The third signature pathology associated with pitpα0/0 mice is a severe hypoglycemia where
circulating glucose (and insulin) levels are nearly an order of magnitude lower than those of
wild-type siblings [157,158]. One major defect appears to be in hepatic gluconeogenesis
with severe deficits in both proglucagon gene expression and in circulating glucagon levels.
As a result, the pitpα0/0 liver inappropriately stores glycogen in the face of a catastrophic
hypoglycemia [158]. As in the case of the CRD, the threshold requirement for PITPα in
maintenance of proper glucose homeostasis is low. Functional PITPα reductions of 90% or
greater are required for manifestation of hypoglycemia [157].
The glucose and gluconeogenic derangements on display in pitpα0/0 neonates are
accompanied by obvious structural derangements of the pancreas. While pitpα0/0 exocrine
pancreas is morphologically normal, the endocrine pancreas is not. The number of
recognizable islets per pitpα0/0 pancreas is strongly reduced relative to wild-type,
vacuolations are evident in the islets, and the pitpα0/0 islet cells themselves are shrunken
[158]. It is not yet known whether these pancreatic deficits are the result of indirect damage
inflicted by a hostile physiological environment (e.g., associated with CRD), or whether
these are manifestations of some other intrinsic developmental problem.
Zebrafish type 1 PITPs
Zebrafish (Danio rerio) express a mammalian-like cohort of type 1 PITPs with the addition
of a unique PITPβ-like protein designated PITPγ [37]. The conservation of Type 1 PITP
Nile et al. Page 21













roster further extends to interesting details of type 1 PITP diversity; in other words,
zebrafish execute precisely the same exon-skipping event as mammals do in generating the
canonical and alternative PITPβ splice variants. As a result, this nonmammalian model is a
facile system for study of vertebrate type 1 PITPs, and it is particularly informative with
respect to the physiological functions of PITPβ isoforms. Whereas functional ablation
experiments have, to this point, been uninformative for the PITPγ isoform, new insights are
forthcoming regarding PITPβ function in this organism. Zebrafish express PITPβ splice
variants predominantly in the eye, specifically in the synaptic pedicles of retinal double cone
cells [37]. Morpholino-based silencing experiments demonstrate PITPβ splice variant
activity is required for the biogenesis and/or maintenance of the double cone photoreceptor
cell outer segments. The deficits in double cone cell outer segment biogenesis and structure
are also reversible. As effectiveness of PITPβ-directed morpholinos wanes with age of the
morphant fish and PITPβ expression is restored, development of morphologically correct
and electrophysiologically functional double cone cells is re-engaged [37].
What functional mechanisms underlie PITPβ splice variant involvement in zebrafish double
cone cell outer segment biogenesis/maintenance? Cone cell outer segments are comprised of
an intricate network of membraneous discs/lamellae. These membranes are subject to a
vigorous course of self-renewal that involves a high-capacity membrane trafficking program
[37,192]. The general localization of PITPβ splice variants to the TGN suggests a scenario
where deficiencies in PITPβ activity subtly compromise Golgi function in double cone cells,
and evoke significant defects in biosynthetic trafficking of opsin into the outer segment. If
the normally high rates of membrane turnover in these structures are maintained in the face
of reduced incorporation of biosynthetic material, outer segment integrity will be
compromised. In mammalian rod cells, the SARA adaptor couples PtdIns-3-P cues to
syntaxin t-SNARE activity in potentiation of the vesicle fusion events involved in outer
segment membrane disc formation and maintenance [193]. One possibility is that zebrafish
PITPβ splice variants support a similarly privileged phosphoinositide-dependent trafficking
pathway in double cone cells.
The zebrafish PITPα studies are surprising in that, unlike in mice, functional ablation of
PITPα results in defective gastrulation. The failure occurs at a stage where highly migratory
cells of the blastoderm extend and converge to cover the yolk cell surface [37]. As in mice,
PtdIns-binding is an essential functional property of PITPα activity in zebrafish
development. The lack of functional redundancy between PITPα and PITPβ isoforms is also
clearly evident – PITPβ does not compensate for PITPα deficits in zebrafish development
[37]. Thus, different vertebrates employ paralogous type 1 PITPs in substantially different
ways.
Conclusion & future perspective
The appropriate spatial and temporal regulation of lipid metabolic flux is central to cellular
homeostasis – even subtle derangements of this system lead to disease. However, we are far
from understanding how diverse territories of the cellular lipid metabolome are interfaced
and how lipid metabolic processes are coordinated with lipid signaling. It is becoming
increasingly clear that Sec14-like PITPs, and likely PITPs in general, contribute to the
integration of diverse aspects of lipid metabolism with phosphoinositide signaling. Physical
pictures of how this may happen are emerging, particularly for Sec14-like proteins and these
models identify new areas for experimental inquiry. Two general areas are ripe for
investigation. First, it will be interesting to discern whether the PtdIns-binding barcodes of
Sec14-like proteins not annotated as PITPs (e.g., caytaxin, CRALBP1 and α-TTP) forecast
authentic inositol-lipid binding capabilities. If so, and it seems likely that it will be so in
some cases, the activities of these proteins, and the etiologies of the associated diseases, will
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need to be re-interpreted. Second, the question of PtdIns-presentation function will be
particularly interesting from the standpoint of Sec14- or PITP-like modules in complex
multidomain proteins. The concept that such PITP-like domains prime production of local
phosphoinositide signals in response to metabolic cues, and that these phosphoinositide
signals in turn modulate catalytic activities of these complex proteins, describes new
conceptual frameworks for how such proteins operate. We expect that Sec14-domains in
particular will garner more attention in this regard and will become increasingly attractive
targets for pharmacological intervention. The importance of being able to visualize, in living
cells, when and where PITPs execute lipid exchange is also clear. Reliable conformational
biosensors will be invaluable tools in those efforts and will provide unique approaches
towards faithfully imaging PITP-regulated interfaces between lipid metabolism and
signaling in vivo.
Finally, we forecast interest in PITPs, and perhaps primarily Sec14-like PITPs, as targets for
pharmaceutical intervention in the context of infectious diseases. While not discussed in this
review, eukaryotic pathogens express PITP-like proteins – some of which are clearly PITPs.
These proteins are sufficiently diverged from their vertebrate paralogs to suggest that
identification of specific small molecule inhibitors will be feasible. It is in this area that
PITP-directed therapies, and a detailed understanding of PITP biology and biochemistry,
may ultimately make the greatest impact in human health.
Executive summary
Phosphatidylinositol transfer proteins & inositol signaling
• Emerging data implicate phosphatidylinositol transfer proteins (PITPs) as
instructors of phosphatidylinositol metabolism, a role that contributes to the
functional diversification of PI signaling.
• PITPs separate into two evolutionarily unrelated classes: the highly conserved
Sec14-like PITPs and the START-domain PITPs.
• Analysis of PITP function has been limited by the inability to describe PITPs
using traditional enzyme definitions.
• Structural and genetic studies on the yeast Sec14 have implicated its role as a
‘nanoreactor’, wherein its primary function is not simple lipid exchange
between membranes, but integration of PtdCho metabolism with presentation of
PtdIns to PtdIns 4-OH kinase.
Sec14-like PITPs in human disease
• Sec14-like proteins can form standalone proteins or be part of more complicated
landscapes within multidomain proteins.
• Malfunctions in Sec14-like domains result in a variety of human disorders
including ataxia with vitamin E deficiency, cayman-type cerebellar ataxia,
visual cycle defects, retinitis punctata albescens and neurofibromatosis type 1.
• Sec14-like proteins, in general, have a conserved PtdIns-binding ‘barcode’.
Mutations within this region often result in protein dysfunction and are well
represented in physiologically relevant mutations.
Physiology of mammalian type I PITPs
• The mammalian type 1 PITPs are structurally unrelated to the Sec14-like PITPs,
but may nonetheless function as nanoreactors.
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• Mice with graded reductions of PITPα expression have been used to dissect the
physiological roles of PITPα. PITPα deficiency results in spinocerebellar
disease, enteric and hepatic steatosis, and hypoglycemia.
• PITPα is implicated in both cell autonomous and cell nonautonomous signaling
mechanisms.
• The roles of type 1 PITPs are being addressed in the zebrafish model system,
describing a role for PITPβ in maintaining outer segment integrity in specific
cone cells.
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Figure 1. Transfer versus nanoreactor models for phosphatidylinositol transfer protein function
(A) Lipid transfer models invoke a vectorial carrier function for PITPs where PtdIns is
transported from membranes of high PtdIns concentration (endoplasmic reticulum) to
relatively PtdIns-poor membranes of the distal compartments of the secretory pathway
which house PtdIns-4-OH kinase activity (TGN/endosomes or plasma membrane). These
models describe productive transfer as involving one heterotypic exchange reaction per
donor and acceptor membrane (i.e., two such exchanges per cycle). (B) The ‘nanoreactor’
model predicts that PITPs stimulate PI4-OH kinase activity by executing multiple rounds of
phospholipid-exchange at a single membrane site. Only heterotypic exchange reactions
generate PtdIns configurations suitable for effective PtdIns presentation.
PI4P: Phosphatidylinositol-4-phosphate; PITP: Phosphatidylinositol transfer protein; PO4:
Phosphate; PtdCho: Phosphatidylcholine; PtdIns: Phosphatidylinositol.
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Figure 2. The Sec14 fold
Crystal structure of two Saccharomyces cerevisiae Sec14-like phosphatidylinositol transfer
proteins. (A) The major yeast PITP, Sec14 is shown in its open conformation (pdb 1AUA –
two bound detergent molecules are excluded). (B) The close Sec14 homolog Sfh1 in its
closed conformation (pdb 3B7Z – bound phospholipid omitted). The β-strands comprising
the floor of the phospholipid-binding pocket are in yellow, while the α-helices that form the
walls of the pocket are in blue. Access to the hydrophobic pocket is mediated by
conformational transitions of the A10/T4 ‘helical gate’ shown in red. The four N-terminal α-
helices (α1–α4) comprise the N-terminal lobe (or ‘tripod motif’) (green).
Nile et al. Page 38













Figure 3. Differential phospholipid-binding strategies by Sec14-like phosphatidylinositol transfer
proteins
Structure of Sfh1 bound to: (A) PtdIns (pdb 3B7Z); (B) PtdCho (pdb 3B7Z). (C) A
description of the configurations of both phosphatidylinositol (PtdIns; gray) and
phosphatidylcholine (PtdCho; black) in the Sfh1/Sec14-fold. The data are from crystals
composed of approximately equal numbers of unit cells of Sfh1 bound to PtdIns and Sfh1
bound to PtdCho (pdb 3B7Z). The A10/T4 ‘helical gate’ that mediates lipid entry is in red,
surrounding α-helices are in blue, the ‘tripod motif’ is in green and β-strands that compose
the floor of the hydrophobic pocket are in yellow. The polar headgroups of PtdIns and
PtdCho bind at distinct sites within the hydrophobic pocket, while the acyl chain space
within the hydrophobic pocket overlaps for these phospholipids.
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Figure 4. The phosphatidylinositol-binding barcode in Sec14-like proteins
(A) Crystal structure of Sfh1 bound to phosphatidylinositol (PtdIns; black; 3B7N)
highlighting residues within the PtdIns binding barcode. The tripod-motif is in green, the
floor of the hydrophobic pocket is in yellow, and the α-helices are in blue with the exception
of the helical gate, which is in red. (B) Orientation of the Sfh1 molecule is rotated by 90°
counterclockwise parallel to the floor. (C) Orientation of the Sfh1 molecule is rotated by
180° counterclockwise parallel to the floor. (D) ClustalX2 alignments of selected Sec14-
superfamily members (identified at right; proteins whose crystal structures have been solved
are indicated with an ‘*’) were superimposed onto the Sfh1 crystal structure using secondary
structural elements as a guide (diagrammed at top). Residues critical for PtdIns headgroup
and backbone coordination are boxed and shaded in cyan – I, coordinate the Ins-headgroup;
II, coordinate the glycerol backbone; III, coordinate the phosphate moiety through which the
Ins headgroup is esterified to the glycerol backbone. Positions of missense substitution
within the PtdIns-binding barcode of the corresponding Sec14-like protein that cause disease
are highlighted by orange boxes.
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Figure 5. Domain arrangements of Sec14-like proteins
Representative Sec14-like proteins are schematized and ordered by general complexity.
Domains of interest are identified. The CRAL-TRIO domain N1 lobe is depicted as a white
circle.
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Figure 6. Phosphatidylinositol transfer proteins α structures
(A) Phosphatidylinositol transfer protein (PITP)-α apo-structure depicting an open
conformation (pdb 1KCM); (B) PtdIns-bound form (pdb 1UW5); (C) PtdCho-bound form
(pdb 1T27). The eight β-strands (yellow) of PITPα comprise the hydrophobic cavity floor
and two α-helices generate the cavity walls (blue). Additional components of PITPα include
a regulatory loop (green), a C-terminal region (red) and a lipid exchange loop (gray).
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Figure 7. Intestinal and hepatic steatosis in phosphatidylinositol transfer proteins in α-deficient
mice
Intestinal slices stained for neutral lipid content with osmium from (A) pitpα+/+ and (B)
pitpα0/0 mice. Note the obvious accumulation of neutral lipid in mutant enterocytes. This
accumulation is dependent on nursing and chases only slowly during periods of fast. The
phenotype Is also obvious in electron micrographs of the villi of duodenal enterocytes from
(C) pitpα+/+ and (D) pitpα0/0 mice (scale bars are 0.2 and 0.5 µM, respectively). Lipid
deposits are highlighted by asterisks. Liver slices stained with osmium from (E) pitpα+/+
and (F) pitpα0/0 mice are also shown.
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Table 1
Other selected Sec14-like proteins.
Gene Protein Description Ref.
BNIP-2 BNIP-2 Proapoptotic and promotes Cdc42-mediated cell elongation through its
Sec14-like domain
[85,194–196]
BNIPL BNIPL/BNIPL2 Proapoptotic, increases cell migration and may play a role in metastasis [85,197,198]
BMCC1/BNIP-XL BMCC1/BNIP-XL Proapoptotic protein highly expressed in the human nervous system.
Interacts with RhoA via Sec14 domain and is a favorable signature in
neuroblastomas
[85,199–202]
BPGAP1 BPGAP1 Promotes pseudopodia formation, Erk signaling. Elevated levels associated
with colorectal cancer and invasive cervical cancer
[203–207]
CRALBPL/RLBP1L1 Clavesin1 Regulates late endosome/lysosome morphology in neurons and is
upregulated in hepatocellular carcinoma
[208–210]
Clavesin2 Regulates late endosome/lysosome morphology in neurons [210]
Sec14L1 SEC14L1 Regulates cholinergic transporters and synaptic vesicle formation [139,211]
Sec14L5 SEC14L5 Unknown [139]
Sec14L2 SEC14L2/TAP1/SPF Plays a role in cholesterol synthesis during fasting. In humans, a potential
link to breast carcinogenesis and prostate cancer
[139,212–216]
Sec14L3 SEC14L3/TAP2/p45 Potential link with drug-induced lung adenocarcinoma in mice [139,217,218]
Sec14L4 SEC14L4/TAP3 Unknown [139]
SESTD1 Solo/HIPLP Elevated levels in the thalamus and brain with potential functions in cone
guidance and smooth muscle contraction
[219,220,210]
MOSPD2 MSPD2 Unknown function in humans but is localized with zebrafish maternal
expression in eggs
[221]
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